Table 4.
Encoded ORF/GP |
Immunogenicity |
Protection |
Ref. | |||
Antibody | CMI | Homologous | Heterologous | |||
DNA vaccine | ORF1-7 | + | + | + | ND | [45,46] |
Subunit vaccine | GP5 | Poor | Poor | - | ND | [47,48] |
Synthetic peptide vaccine | GP5 | - | - | ND | - | [13] |
Adenovirus vector vaccine | GP3, 4, 5 | + | + | ND | ND | [49-51] |
PRV vector vaccine | GP5, M | + | + | + | ND | [52,53] |
Poxvirus vector vaccine | GP3, 5, M | + | + | + | ND | [54,55] |
TGEV vector vaccine | GP5, M | + | ND | + | ND | [56] |
Alphavirus-derived replicon | GP5, M | + | + | + | + | [57] |
Bacterial vector vaccine | GP5, M | + | - | + | ND | [58] |
Insect cell-derived vaccine | ORF3, 5, 7 | + | ND | + | ND | [59] |
Plant-derived vaccine | GP5 | + | + | ND | ND | [60,61] |
Gene-deleted MLV (deleted15-mer nsp2 epitope) | + | ND | ND | ND | [65] |
+: Success; -: Failure; ND: Not determined.